CAMBRIDGE, Mass., June 30, 2014 /PRNewswire/ -- Minerva Neurosciences, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases, today announced the pricing of its initial public offering of 5,454,545 shares of its common stock at a public offering price of $6.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "NERV" on July 1, 2014. In addition, Minerva has granted the underwriters a 30-day option to purchase up to an additional 818,181 shares of common stock at the same price. The offering is expected to close on July 7,
2014, subject to customary closing conditions.
Jefferies LLC is acting as sole book-running manager for the offering. Robert W. Baird & Co. Incorporated and JMP Securities LLC are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 30, 2014. The offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340 or by email at prospectus_department@jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Media contact:
Jennifer Ringler
Berry & Company Public Relations
212.253.8881
jringler@berrypr.com
Investor contact:
Renee Leck
Stern Investor Relations
212.362.1200
renee@sternir.com
SOURCE Minerva Neurosciences, Inc.
